Larson Financial Group’s Amicus Therapeutics FOLD Stock Holding History

Larson Financial Group’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-373	Closed	-$5.39K	–	3833
2026 Q1	$5.39K	Buy	373 +71	+24%	+$1.02K	﹤0.01%	2571
2025 Q4	$4.3K	Sell	302 -487	-62%	-$4.78K	﹤0.01%	2517
2025 Q3	$6.22K	Buy	789 +289	+58%	+$2.06K	﹤0.01%	2271
2025 Q2	$2.87K	Buy	+500	New	+$3.23K	﹤0.01%	2287
2025 Q1	–	Sell	-1,400	Closed	-$13.2K	–	3115
2024 Q4	$13.2K	Hold	1,400	–	–	﹤0.01%	1386
2024 Q3	$15K	Buy	+1,400	New	+$15.2K	﹤0.01%	1324
2023 Q4	–	Sell	-81	Closed	-$985	–	1838
2023 Q3	$985	Buy	+81	New	+$1.04K	﹤0.01%	1494

Other funds holding FOLD

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Larson Financial Group's FOLD Position: Q2 2026 in Review

Larson Financial Group sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 373 shares — an estimated $5.39K sold.

Larson Financial Group first reported a position in FOLD in Q3 2023 and held it in 7 quarters. The position peaked at $15K in Q3 2024. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

Larson Financial Group reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
Larson Financial Group sold 373 Amicus Therapeutics shares in Q2 2026, an estimated $5.39K.
Larson Financial Group first reported a position in Amicus Therapeutics in Q3 2023 and held it in 7 quarters.
Larson Financial Group's Amicus Therapeutics position peaked at $15K in Q3 2024.
2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.